¶ÈÀÓ¾Ò²ð

2015ǯ

¸¶ÃøÏÀʸ¡¿¾ÉÎãÊó¹ð

  1. Aoki Y, Ishii R, Pascual-Marqui RD, Canuet L, Ikeda S, Hata M, Imajo K, Matsuzaki H, Musha T, Asada T, Iwase M, Takeda M ; Detection of EEG -resting state independent networks by eLORETA- ICA method¡¥Frontiers in human neuroscience ; 9:Article No.31¡¤2015
  2. Aoki Y, Kazui H, Tanaka T, Ishii R, Wada T, Ikeda S, Hata M, Canuet L, Katsimichas T, Musha T, Matsuzaki H, Imajo K, Kanemoto H, Yoshida T, Nomura K, Yoshiyama K, Iwase M, Takeda M ; Noninvasive prediction of shunt operation outcome in idiopathic normal pressure hydrocephalus¡¥Scientific Reports ; 5:7775¡¤2015
  3. Biernacka JM, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Baune BT, Kato M, Liu YL, Praphanphoj V, Stingl JC, Tsai SJ, Kubo M, Klein TE, Weinshilboum R ; The International SSRI Pharmacogenomics Consortium (ISPC) a genome-wide association study of antidepressant treatment response¡¥Translational psychiatry ; 5:e553¡¤2015
  4. Faber PL, Lehmann D, Gianotti LR, Milz P, Pascual-Marqui RD, Held M, Kochi K ; Zazen meditation and no-task resting EEG compared with LORETA intracortical source localization¡¥Cogn Process ; 16(1):87-96¡¤2015
  5. Harada E, Kato M, Fujikoshi S, Wohlreich MM, Berggren L, Tokuoka H ; Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trials¡¥International journal of clinical practice ; 69(10):1139-1148¡¤2015
  6. Ikeda S, Kazui H, Tanaka T, Ishii R, Aoki Y, Hata M, Canuet L, Yoshiyama K, Iwase M, Pascual-Marqui RD, Takeda M ; Association of cerebrospinal fluid tap-related oscillatory activity and shunt outcome in idiopathic normal-pressure hydrocephalus¡¥Psychogeriatrics ; 15(3):191-197¡¤2015
  7. Kato M, Kimura T, Kimura T, Hara T ; Safety and effectiveness of controlled-release paroxetine in routine clinical practice: results of a postmarketing surveillance study of patients with depression¡¥Neuropsychiatric Disease and Treatment ; 11:435-452¡¤2015
  8. Kato M, Serretti A, Nonen S, Takekita Y, Wakeno M, Azuma J, Kinoshita T ; Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs¡¥Translational Psychiatry ; 5:e513¡¤2015
  9. Kyo M, Mii H, Takekita Y, Tokuhara D, Yazaki M, Nakamori Y, Kono S, Kinoshita T ; Case of adult-onset type II citrullinemia treated as schizophrenia for a long time¡¥Psychiatry and clinical neurosciences ; 69(5): 306-307¡¤2015
  10. Milz P, Faber PL, Lehmann D, Koenig T, Kochi K, Pascual-Marqui RD ; The functional significance of EEG microstates -Associations with modalities of thinking¡¥Neuroimage ; 125:643-656¡¤2015
  11. Nishida K, Razavi N, Jann K, Yoshimura M, Dierks T, Kinoshita T, Koenig T ; Integrating Different Aspects of Resting Brain Activity: A Review of Electroencephalographic Signatures in Resting State Networks Derived from Functional Magnetic Resonance Imaging¡¥Neuropsychobiology ; 71(1):6-16¡¤2015
  12. Ohtani T, Bouix S, Lyall AE, Hosokawa T, Saito Y, Melonakos E, Westin CF, Seidman LJ, Goldstein J, Mesholam-Gately R, Petryshen T, Wojcik J, Kubicki M ; Abnormal white matter connections between medial frontal regions predict symptoms in patients with first episode schizophrenia¡¥Cortex ; 71:264–276¡¤2015
  13. Ozaki N, Otsubo T, Kato M, Higuchi T, Ono H, Kamijima K, ADMIRE Study Group ; Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: A subgroup analysis and Montgomery-Asberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study¡¥Psychiatry and clinical neurosciences ; 69(1):34-42¡¤2015
  14. Suwa A, Nishida K, Utsunomiya K, Nonen S, Yoshimura M, Takekita Y, Wakeno M, Tajika A, Yoshino M, Koshikawa Y, Kato M, Kinoshita T ; Neuropsychological Evaluation and Cerebral Blood Flow Effects of Apolipoprotein E4 in Alzheimer's Disease Patients after One Year of Treatment: An Exploratory Study¡¥Dement Geriatr Cogn Disord Extra ; 5:414-423¡¤2015
  15. Takekita Y, Fabbri C, Kato M, Nonen S, Sakai S, Sunada N, Koshikawa Y, Wakeno M, Okugawa G, Kinoshita T, Serretti A. ; Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial¡¥European archives of psychiatry and clinical neuroscience ; 265(7):579-588¡¤2015
  16. Takekita Y, Fabbri C, Kato M, Nonen S, Sakai S, Sunada N, Koshikawa Y, Wakeno M, Okugawa G, Kinoshita T, Serretti A ; HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia¡¥Journal of clinical psychopharmacology ; 35(3):220-227¡¤2015
  17. Takekita Y, Fabbri C, Kato M, Nonen S, Sakai S, Sunada N, Koshikawa Y, Wakeno M, Okugawa G, Kinoshita T, Serretti A. ; Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients¡¥Neuropsychobiology ; 72(2):118-125¡¤2015
  18. Takekita Y, Fabbri C, Kato M, Koshikawa Y, Tajika A, Kinoshita T, Serretti A ; HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis¡¥The international journal of neuropsychopharmacology ; Epub ahead of print¡¤2015
  19. Æ£»³²íÀ², ÅĶᰡÍö, ¾åÌîÀéÊæ, »°°æ ¹À, ºû²¬²ÂÈþ, Ë̱ºÊ¡»Ò, µÈÌî¿¿µª, ²¬Â¼¹¨Èþ, ´Ý»³ÃÒÈþ, ÌÚ²¼Íøɧ ; ¹­ÈÆÀ­È¯Ã£¾ã³²¤Ë¤ª¤±¤ë²ÈÄí´Ä¶­°ø¤Î±Æ¶Á¡ÝPARSû½ÌÈǤβòÀϤ«¤é¡Ý¡¥ºÇ¿·Àº¿À°å³Ø ; 20(5):435-439¡¤2015
  20. ¼ºê¸÷Ë®, Àж¿²¬ ½ã, ÌÚ²¼Íøɧ, ÃÝÆâ±þ³È, ÅìëÃÒ·ÃÍý, ÅçÆâ½ç°ìϺ ; QuetiapineÂè­¶Áê»î¸³¡§´û¸¤Î¹³¤¦¤ÄÌô¤Ç¸ú²ÌÉÔ½½Ê¬¤ÊÂ礦¤ÄÉÂÀ­¾ã³²´µ¼Ô¤òÂоݤȤ·¤¿¥×¥é¥»¥ÜÂоÈÆó½ÅÌÕ¸¡·²´ÖÈæ³Ó»î¸³¡¥Î×¾²Àº¿ÀÌôÍý ; 18(12):1613-1625¡¤2015
  21. À¾ÅÄ ·½°ìϺ, Pascual-Marqui Roberto, Ë̱º Í´°ì, µÈ¼ ¶©»Ë, »°°æ ¹À, °ëë ½ÓÌÀ, ÌÚ²¼ Íøɧ ; sLORETA¤Ë¤ª¤±¤ë²òÀÏË¡¤Ë´Ø¤·¤Æ¤Î¸¡Æ¤ ¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼·¿Ç§Ãξɴµ¼Ô¤Ë¤ª¤±¤ëfunctional connectivity¤Ë¤Ä¤¤¤Æ¡¥ÆüËÜÌôʪǾÇȳزñ»¨»ï ; 16(1):43-46¡¤2015.
  22. »³Â¼²ÂÂå, °ÂÅļéÎÉ, ÈÄÅ칧²ð, Ê¡ÅÄÂÙɧ, ÌÚ²¼Íøɧ ; ÁжËÀ­¾ã³²¤Îí¯¾É¾õ´µ¼Ô¤ËÂФ¹¤ëaripiprazole¤ÎÍ­¸úÀ­¡¦°ÂÁ´À­¤Ë¤Ä¤¤¤Æ¤Î¸¡Æ¤¡ÝÆÃÄê»ÈÍÑÀ®ÀÓÄ´ºº¤ÎÃæ´Ö²òÀÏ·ë²Ì¡Ý¡¥Î×¾²Àº¿ÀÌôÍý ; 18(3):305-315¡¤2015
  23. µÈÌî¿¿µª, ²¬Â¼¹¨Èþ, ´Ý»³ÃÒÈþ, ÃæÊ¿¶Ç»Ò, Í­ÌڱʻÒ, ÎëÌÚÊþ»Ò, »³ÅÄÈÞº»»Ò, ÅĶᰡÍö, ¿¥ÅÄ͵¹Ô, ÌÚ²¼Íøɧ ; À­Æ±°ìÀ­¾ã³²¤Ë¤ª¤±¤ëÃÎŪ¦Ì̤ÎÆÃħ Female to male¤Î¸À¸ìÀ­IQ¤ÈÆ°ºîÀ­IQ¤Î¥Ç¥£¥¹¥¯¥ì¥Ñ¥ó¥·¡¼¤ËÃåÌܤ·¤Æ¡¥¥á¥ó¥¿¥ë¥Ø¥ë¥¹²¬Ëܵ­Ç°ºâÃĸ¦µæ½õÀ®Êó¹ð½¸ ; 26:115-119¡¤2015

¥Ú¡¼¥¸TOP¤ØÌá¤ë

ÁíÀ⡦²òÀâ

  1. Ikeda S, Mizuno-Matsumoto Y, Canuet L, Ishii R, Aoki Y, Hata M, Katsimichas T, Pascual-Marqui RD, Hayashi T, Okamoto E, Asakawa T, Iwase M, Takeda M ; Emotion Regulation of Neuroticism: Emotional Information Processing Related to Psychosomatic State Evaluated by Electroencephalography and Exact Low-Resolution Brain Electromagnetic Tomography¡¥Neuropsychobiology ; 71(1):34-41¡¤2015
  2. ÃÓÅĽӰìϺ ; ÂçºåÉܲ¼¤ÎÌôʪ°Í¸ÌäÂê¡¥ÂçºåÊݸ±°å»¨»ï ; 586:14-17¡¤2015
  3. ²ÃÆ£Àµ¼ù, ÖÖË̲µ± ; °äÅÁÌôÍý³Ø¤ÎÎ×¾²±þÍѡݹ³¤¦¤ÄÌô¡¢¹³Àº¿ÀÉÂÌô¤Î¸ÄÊÌ°åÎÅ¡Ý¡¥Àº¿À²Ê¼£ÎÅ³Ø ; 30(1):31-40¡¤2015
  4. ²ÃÆ£Àµ¼ù ; DSM-5¤Ë¤ª¤±¤ëÁжËÀ­¾ã³²¤È¤¦¤ÄÉ¡ÝÎ×¾²¡¦¸¦µæ¤Ç¤ÎÍ­ÍѤʻȤ¤Êý¤ò¹Í¤¨¤Æ¤ß¤ë¡Ý¡¥Àº¿À¿À·Ð³Ø»¨»ï ; 117(10):837-843¡¤2015
  5. ²ÃÆ£Àµ¼ù ; ÈóÄê·¿¹³Àº¿ÀÉÂÌô¤ÎÊä½¼ÎÅË¡¤Î¸ú²Ì¤ÈÌäÂêÅÀ¤ò¤É¤¦Ç§¼±¤¹¤Ù¤­¤«¡¥Î×¾²Àº¿ÀÌôÍý ; 18(10):1277-1284¡¤2015
  6. ²ÃÆ£Àµ¼ù ; “¥¨¥Ó¥Ç¥ó¥¹×°äÅÁŪÇØ·Ê”¤Ç¹Í¤¨¤ëÆüËܿͤΤ¦¤Äɼ£ÎÅ¡¥Î×¾²Àº¿ÀÌôÍý ; 18(4):459-465¡¤2015
  7. Ë̸µ ·ò, ¾åÛêµÈ¿Í ; ¤Ê¤¼?¤É¤¦¤·¤Æ?¤³¤ó¤Ê¤È¤­¤É¤¦¤·¤è¤¦?¤ò¥¨¥Ó¥Ç¥ó¥¹¤Ä¤­¤Ç²ò·è! µßµÞ´Ç¸î¤ª¤¿¤¹¤±Q&A 99¡ÝÆɼԤÎÀ¸¤Î¥®¥â¥ó¤ËÅú¤¨¤Þ¤¹!¡Ý (Âè2¾Ï)¥Û¥¹¥Ô¥¿¥ë¥±¥¢ÊÔ ½é´ü¼£ÎÅ Àº¿À²ÊµßµÞ¤Î½é´üÂбþ (Q47)Àº¿À²ÊµßµÞ¤Î¸½¾õ¤ò¶µ¤¨¤Æ¤¯¤À¤µ¤¤¡¥EMERGENCY CARE ; 2015¿·½ÕÁý´©:114-115¡¤2015
  8. Ë̸µ ·ò, ¾åÛêµÈ¿Í ; ¤Ê¤¼?¤É¤¦¤·¤Æ?¤³¤ó¤Ê¤È¤­¤É¤¦¤·¤è¤¦?¤ò¥¨¥Ó¥Ç¥ó¥¹¤Ä¤­¤Ç²ò·è! µßµÞ´Ç¸î¤ª¤¿¤¹¤±Q&A 99¡ÝÆɼԤÎÀ¸¤Î¥®¥â¥ó¤ËÅú¤¨¤Þ¤¹!¡Ý (Âè2¾Ï)¥Û¥¹¥Ô¥¿¥ë¥±¥¢ÊÔ ½é´ü¼£ÎÅ Àº¿À²ÊµßµÞ¤Î½é´üÂбþ (Q48)Ìë´Ö¤ËÀº¿À²Ê´µ¼Ô¤¬Í象¤·¤¿¤é¡¢¤É¤¦Âбþ¤¹¤ì¤Ð¤¤¤¤¤Î?¡¥EMERGENCY CARE ; 2015¿·½ÕÁý´©:116-117¡¤2015
  9. Ë̸µ ·ò, ¾åÛêµÈ¿Í ; µÞÀ­ÃæÆǡݲ¡¤µ¤¨¤Æ¤ª¤¯¤Ù¤­Ãθ«¤È¿ÇÎÅ¤Î¼ÂºÝ ÃæÆÇ¿ÇÎŤȥá¥ó¥¿¥ë¥Ø¥ë¥¹¡¥µßµÞ°å³Ø ; 39(7):841-844¡¤2015
  10. Ë̸µ ·ò, ¾åÛêµÈ¿Í ; °ìÈÌÆâ²Ê¿ÇÎŤÇÌòΩ¤Ä¤¦¤ÄɤÎÃμ±¡Ý¤³¤³¤í¤ÎÌäÂê¤Ë¤É¤¦Âн褹¤ë¤« ÆÃÄê¤Î¾ìÌ̤ˤª¤±¤ë¤¦¤Ä¾õÂ֤ؤÎÂбþ µßµÞ¿ÇÎÅ¡¥Æâ²Ê ; 115(2):249-252¡¤2015
  11. Ë̸µ ·ò ; Æâ²Ê¼À´µ¤Î¿ÇÃÇ´ð½à¡¦É·¿Ê¬Îࡦ½Å¾ÉÅÙ (Âè8¾Ï)ÃæÆÇ Ã×»àÀ­¥¬¥¹(°ì»À²½ÃºÁÇ,β²½¿åÁÇ)ÃæÆÇ¡¥Æâ²Ê ; 115(6):1260-1261¡¤2015
  12. Ë̸µ ·ò ; ¤³¤ì¤Ï²¿¤ÎÃæÆÇ!?ÃæÆǵ¯°øʪ¼Á¤ÎƱÄê¤Èɾ²Á Î×¾²¾É¾õ¡¦¸¡ººÃͤȤ½¤Î·Ð»þÊѲ½¤Ë¤è¤ëÃæÆǵ¯°øʪ¼Á¤Î¿äÄê¡¥Ìô¶É ; 66(11):2838-2842¡¤2015
  13. ¼¾åµ®±É, µÈ¼¶©»Ë, ÌÚ²¼Íøɧ ; Àº¿À¾ã³²¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó¤Î¸½¾õ¤È̤Íè Àº¿À²Ê¥Ç¥¤¥±¥¢¤Î¤³¤ì¤«¤é¤ÎÌò³ä¡¥ºÇ¿·Àº¿À°å³Ø ; 20(2):99-105¡¤2015
  14. ¹âÌî È» ; ¥Õ¥Ã¥È¥µ¥ë¤òÄ̤·¤Æ¥ê¥«¥Ð¥ê¡¼¤¹¤ë ¡Ì»öÎã­£¡ÍÌò³ä¤Î¸ú²Ì¡Ý¥­¥ã¥×¥Æ¥ó¤Ë¤Ê¤Ã¤¿¤³¤È¤òµ¡¤ËÊѲ½¤·¤¿»öÎã¡Ý¡¥Î×¾²ºî¶ÈÎÅË¡ ; 12(2):134-136¡¤2015
  15. ÖÖË̲µ±, ÌÚ²¼Íøɧ ; ¥¢¥ê¥Ô¥×¥é¥¾¡¼¥ë¿åÏÂʪ»ý³À­Ãí¼ÍºÞ(¥¨¥Ó¥ê¥Õ¥¡¥¤»ý³À­¿å·ü¶ÚÃíÍÑ)¡¥ºÇ¿·Àº¿À°å³Ø ; 20(4):333-340¡¤2015
  16. ÖÖË̲µ±, ²ÃÆ£Àµ¼ù ; Î×¾²¸¦µæ¤Ë´Ø¤¹¤ëÎÑÍý»Ø¿Ë¤Ï¤É¤¦¤Ê¤ë¡©¡Ý¿·»Ø¿Ë²¼¤Ç¤ÎÀº¿À²ÊÎ×¾²¸¦µæ¤ÎŸ˾¡Ý¡¥Àº¿À²Ê ; 27(2):142-150¡¤2015
  17. ÖÖË̲µ±, ²ÃÆ£Àµ¼ù ; Åý¹ç¼ºÄ´¾É¤Î¥²¥Î¥àÌôÍý³Ø¤È¼£ÎÅÈ¿±þͽ¬¡¥Ê¬»ÒÀº¿À°å³Ø ; 15(4):266-273¡¤2015

¥Ú¡¼¥¸TOP¤ØÌá¤ë

Ãø½ñ

  1. ÃÓÅĽӰìϺ ; Âè13¾Ï ʪ¼Á´ØÏ¢¾ã³²¤ª¤è¤ÓÓÏÊÊÀ­¾ã³²·² 6.Àº¿À»É·ãÌô´ØÏ¢¾ã³²·²(³Ð¤»¤¤ºÞ¤Ê¤É)¡¥Àº¿À²Ê¼£ÎųØ30´¬Áý´©¹æ Àº¿À²Ê¼£ÎŤˤª¤±¤ë½èÊý¥¬¥¤¥É¥Ö¥Ã¥¯ ; 284-288 À±Ï½ñŹ¡¤2015
  2. ²ÃÆ£Àµ¼ù ; 9.Ìôʪȿ±þÀ­¤Î¥Ð¥¤¥ª¥Þ¡¼¥«¡¼ 9-1.¹³¤¦¤ÄÌô¡¥Àº¿À¼À´µ¤Î¥Ð¥¤¥ª¥Þ¡¼¥«¡¼ ; 193-214 À±Ï½ñŹ¡¤2015
  3. ²ÃÆ£Àµ¼ù ; ¼£ÎŤËÆñ½Â¤¹¤ë¤¦¤Ä¾õÂ֤οÇÃǤȴ²²ò¤Ø¤Î¼¡¤Î°ì¼ê¡¥Àº¿À°å³Ø¤Î´ðÈ×[2] ¤¦¤ÄÉ¿ÇÎŤÎÏÀÍý¤ÈÎÑÍý ; 145-157 ³Ø¼ù½ñ±¡¡¤2015
  4. ²ÃÆ£Àµ¼ù ; ¥Ù¥ó¥é¥Õ¥¡¥­¥·¥ó¡¥¤³¤³¤í¤Î¼£ÎÅÌô¥Ï¥ó¥É¥Ö¥Ã¥¯ Âè10ÈÇ ; 68-69 À±Ï½ñŹ¡¤2015
  5. µÆÃϽӶÇ, ¿Î²¦¿ÊÂÀϺ, ¿ù»³Äª¹¨, ÅÏî´¹Õ°ìϺ, ÎëÌÚ±ÇÆó, ²ÃÆ£Àµ¼ù ; £Ö¾Ï ¹³¤¦¤ÄÌô¡¥Àº¿À²ÊÌôʪÎÅË¡ ¥°¥Ã¥É¥×¥é¥¯¥Æ¥£¥¹¡Ý¥ï¥ó¥é¥ó¥¯¾å¤Î½èÊý¤ò¤á¤¶¤·¤Æ¡Ý ; 81-101 ¿·¶½°å³Ø½ÐÈǼҡ¤2015
  6. Ë̸µ ·ò ; »°´Ä·Ï¹³¤¦¤ÄÌôÃæÆÇ¡¢Ãº»À¥ê¥Á¥¦¥àÃæÆÇ¡¥º£Æü¤Î¼£ÎÅ»Ø¿Ë ; 159-162 °å³Ø½ñ±¡¡¤2015
  7. Ë̱ºÍ´°ì ; Âè2¾Ï¾É¾õ¤ò¸«¶Ë¤á¤è¤¦ 5.¤Æ¤ó¤«¤óŽ¥¤±¤¤¤ì¤ó¡¥¤¬¤ó´µ¼Ô¤ÎÀº¿À¾É¾õ¤Ï¤³¤¦¿Ç¤ë ¸þÀº¿ÀÌô¤Ï¤³¤¦»È¤¦ ; 100-111 ¤¸¤Û¤¦¡¤2015
  8. À¾ÅÄ·½°ìϺ ; ¤Ï¤¸¤á¤Ë¡¥14th CADP Êó¹ð½ñ ; 7 JYPO¡¤2015
  9. óîÆ£¹¬»Ò ; Àº¿ÀÎÏưŪ»ëÅÀ¤¬Í­¸ú¤Ç¤¢¤ë¾ì¹ç¤Ï¤¢¤ë¤Î¤«¡¥Àº¿À²ÊÎ×¾²¥µ¡¼¥Ó¥¹ ¡ÚÆý¸¡ÛÌÀÆü¤«¤é¤Ç¤­¤ë¶¯Ç÷¾É/¶¯Ç÷À­¾ã³²¤Î¿ÇÎÅ­µ ; 15(1):71-76 À±Ï½ñŹ¡¤2015
  10. º½Åľ°¹§, ²ÃÆ£Àµ¼ù ; Âè3¾Ï ¼£ÎŤˤª¤±¤ë¹³ÉÔ°ÂÌô¤Î°ÕµÁ¤È»È¤¤Êý 7.½÷À­¥Û¥ë¥â¥ó¤ÈÉ԰¾㳲¡¥¹³ÉÔ°ÂÌô¥×¥é¥¯¥Æ¥£¥«¥ë¥¬¥¤¥É º£¤À¤«¤éÃΤäƤª¤­¤¿¤¤Àµ¤·¤¤»È¤¤Êý ; 129-135 Ãæ³°°å³Ø¼Ò¡¤2015
  11. ÖÖË̲µ±, ²ÃÆ£Àµ¼ù ; Âè2Éô ¸þÀº¿ÀÌô¤Î»È¤¤Êý¤Î¥³¥Ä¤ÈÃí°ÕÅÀ Âè1¾Ï ¹³Àº¿ÀÉÂÌô¡¥Àº¿À²ÊÌôʪ¼£ÎÅ ¤³¤ó¤Ê¤È¤­¤É¤¦¤¹¤ë¤Ù¤­¤« ; 10-27 °å³Ø½ñ±¡¡¤2015
  12. µÈ¼¶©»Ë ; Âè3¾ÏÌô¤ò»È¤¤¤³¤Ê¤½¤¦ 5.¹³¤Æ¤ó¤«¤óÌô¡¥¤¬¤ó´µ¼Ô¤ÎÀº¿À¾É¾õ¤Ï¤³¤¦¿Ç¤ë ¸þÀº¿ÀÌô¤Ï¤³¤¦»È¤¦ ; 166-180 ¤¸¤Û¤¦¡¤2015

¥Ú¡¼¥¸TOP¤ØÌá¤ë

2014ǯ

¸¶ÃøÏÀʸ¡¿¾ÉÎãÊó¹ð

  1. Kanba S, Kawasaki H, Ishigooka J, Sakamoto K, Kinoshita T, Kuroki T ; A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study).The world journal of biological psychiatry ; 15(2):113-121¡¤2014
  2. Kawanishi C, Aruga T, Ishizuka N, Yonemoto N, Otsuka K, Kamijo Y, Okubo Y, Ikeshita K, Sakai A, Miyaoka H, Hitomi Y, Iwakuma A, Kinoshita T, Akiyoshi J, Horikawa N, Hirotsune H, Eto N, Iwata N, Kohno M, Iwanami A, Mimura M, Asada T, Hirayasu Y ; Assertive case management versus enhanced usual care for people with mental health problems who had attempted suicide and were admitted to hospital emergency departments in Japan (ACTION-J): a multicentre, randomised controlled trial.The Lancet Psychiatry ; 1(3):193-201¡¤2014
  3. Kyo M, Mii H, Takekita Y, Tokuhara D, Yazaki M, Nakamori Y, Kono S, Kinoshita T ; Case of adult-onset type­¶ citrullinemia treated as schizophrenia for a long time.Psychiatry and clinical neurosciences ; Epub ahead of print¡¤2014
  4. Lehmann D, Faber PL, Pascual-Marqui RD, Milz P, Herrmann WM, Koukkou M, Saito N, Winterer G, Kochi K ; Functionally aberrant electrophysiological cortical connectivities in first episode medication-naive schizophrenics from three psychiatry centers.Frontiers in Human Neuroscience ; 8:1-9¡¤2014
  5. Milz P, Faber PL, Lehmann D, Kochi K, Pascual-Marqui RD ; sLORETA intracortical lagged coherence during breath counting in meditation-naïve participants.Frontiers in Human Neuroscience ; 8:303¡¤2014
  6. Ohtani T, Nestor PG, Bouix S, Saito Y, Hosokawa T, Kubicki M ; Medial Frontal White and Gray Matter Contributions to General Intelligence.PLoS One ; 9(12):1-17¡¤2014
  7. Ohtani T, Bouix S, Hosokawa T, Saito Y, Eckbo R, Ballinger T, Rausch A, Melonakos E, Kubicki M ; Abnormalities in white matter connections between orbitofrontal cortex and anterior cingulate cortex and their associations with negative symptoms in schizophrenia: A DTI study.Schizophrenia research ; 157(1-3):190-197¡¤2014
  8. Painold A, Faber PL, Milz P, Reininghaus EZ, Holl AK, Letmaier M, Pascual-Marqui RD, Reininghaus B, Kapfhammer HP, Lehmann D ; Brain electrical source imaging in manic and depressive episodes of bipolar disorde.Bipolar disorders ; 16(7):690-702¡¤2014
  9. Pascual-Marqui RD, Biscay RJ, Bosch-Bayard J, Lehmann D, Kochi K, Kinoshita T, Yamada N, Sadato N ; Assessing direct paths of intracortical causal information flow of oscillatory activity with the isolated effective coherence (iCoh).Frontiers in human neuroscience ; 8:448(1-12)¡¤2014
  10. Pascual-Marqui RD, Lehmann D, Faber P, Milz P, Kochi K, Yoshimura M, Nishida K, Isotani T, Kinoshita T ; The resting microstate networks (RMN): cortical distributions, dynamics, and frequency specific information flow.ARXIV.ORG ; pre-print¡¤2014
  11. °ëë½ÓÌÀ, Ê÷´ßͳµª»Ò, µÈ¼¶©»Ë, À¾ÅÄ·½°ìϺ, »°°æ ¹À, Ë̱ºÍ´°ì, ¿¥ÅÄ͵¹Ô, Pascual-Marqui RD, ÌÚ²¼Íøɧ ; ¼ï¡¹¤ÎºÅ̲°Å¼¨¤¬Ç¾ÅÅ°ÌÌ©ÅÙʬÉÛ¤Èfunctional connectivity¤Ë¤ª¤è¤Ü¤¹±Æ¶Á¡¥ºÅ̲¤È²Ê³Ø ; 28(1):41-49¡¤2014
  12. ±ÛÀîÍÛ²ð, ÖÖË̲µ±, µÈ¼¶©»Ë, ÎëÌÚÈþº´, À¾ÅÄ·½°ìϺ, ¿Ûˬ °´, ÅĶᰡÍö, ºä°æ»ÖÈÁ, µÈÌî¿¿µª, ²ÃÆ£Àµ¼ù, ÌÚ²¼Íøɧ ; ¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼·¿Ç§Ãξɴµ¼Ô¤¬¹³Ç§ÃξÉÌô¤òĹ´üÉþÌô¤¹¤ë°ø»Ò¤Ï²¿¤« donepezil¤Èmemantine¤Î¸åÊý»ëŪ¸¡Æ¤¤«¤é.Geriatric Medicine ; 52(6):685-690¡¤2014
  13. µö Á´Íø, À¾ÅÄ·½°ìϺ, »°°æ ¹À, Ë̱ºÍ´°ì, ÖÖË̲µ±, ²ÃÆ£Àµ¼ù, ¹âÀ¥¾¡¶µ, ¹â¶¶¹¬Íø, ÌÚ²¼Íøɧ ; ¹âÎðÃËÀ­¤Ëȯ¾É¤·¤¿¹³NMDA¼õÍÆÂÎǾ±ê¤Î¾ÉÎã.ϷǯÀº¿À°å³Ø»¨»ï ; 25(10):1153-1159¡¤2014
  14. ÎëÌÚÈþº´ ; ǧÃξɹâÎð¼Ô¤¬Å¬Àڤ˳°ÍèÄ̱¡¤òĹ´ü´Ö·Ñ³¤¹¤ë¤¿¤á¤ËɬÍפʼҲñ»ñ¸»¡¦¼Ò²ñŪ¦Ì̤θ¡¾Ú.ÂçºåǧÃξɸ¦µæ²ñǯÊó ; 23:83-97¡¤2014
  15. »³ËÜÆØ»Ò, »ÍËܤ«¤ä¤Î, Ë̸µ ·ò, »³ÅÄÈÞº»»Ò, µÈ¼¶©»Ë, ÌÚ²¼Íøɧ ; ¼«»¦Ì¤¿ë¼Ô¤ËÂФ¹¤ëÀº¿À²Êºî¶ÈÎÅË¡²ðÆþ¤Î²ÄǽÀ­ ¡½µÞÀ­°ì»À²½ÃºÁÇÃæÆǤξÉÎã¤òÄ̤·¤Æ¡½.ºî¶ÈÎÅË¡ ; 33(5):432-441¡¤2014
  16. µÈÌî¿¿µª, »³ËÜÆØ»Ò, ²¬Â¼¹¨Èþ, ¿ù»³Í´É×, ¼¾åµ®±É, ¹âÌî È», À¾ÅÄ·½°ìϺ, µÈ¼¶©»Ë, ÌÚ²¼Íøɧ ; µÙ¿¦Ãæ¤Î¿À·Ð¾É¤ª¤è¤Ó¤¦¤ÄÉ´µ¼Ô¤ËÂФ¹¤ë½¸ÃÄǧÃιÔÆ°ÎÅË¡ ¡½¥ê¥ï¡¼¥¯¥×¥í¥°¥é¥à¼Â»Ü¾å¤Îº¤ÆñÅÀ¤«¤é¤Î¸¡Æ¤¡½.¥á¥ó¥¿¥ë¥Ø¥ë¥¹²¬Ëܵ­Ç°ºâÃĸ¦µæ½õÀ®Êó¹ð½¸ ; (25):133-138¡¤2014

¥Ú¡¼¥¸TOP¤ØÌá¤ë

ÁíÀ⡦²òÀâ

  1. Kito S, Pascual-Marqui RD, Hasegawa T, Koga Y ; High-frequency Left Prefrontal Transcranial Magnetic Stimulation Modulates Resting EEG Functional Connectivity for Gamma Band Between the Left Dorsolateral Prefrontal Cortex and Precuneus in Depression.Brain stimulation ; 7(1):145-146¡¤2014
  2. Michel CM, Brandeis D, Witte H, Wackermann J, Kochi K, Gianotti L, Faber P, Milz P, Pascual-Marqui RD, König T, Kinoshita T, Strik W, Skrandies W ; In memoriam: Dietrich Lehmann, 1929–2014.Brain Topography ; 27(5):611-612¡¤2014
  3. ²ÃÆ£Àµ¼ù, ÖÖË̲µ±, Serretti A ; ¥¤¥¿¥ê¥¢¤ÇÀº¿À²Ê¸¦µæα³Ø¤¹¤ë¤È¤¤¤¦¤³¤È¡½¥Ü¥í¡¼¥Ë¥ãÂç³Øα³Ø·Ð¸³¤è¤ê¡½.Àº¿À²Ê ; 25(2):180-186¡¤2014
  4. ²ÃÆ£Àµ¼ù ; °äÅÁ»Ò¥Þ¡¼¥«¡¼¤Ë¤è¤ë¸ÄÊ̲½¼£ÎŤβÄǽÀ­¤È²ÝÂê.Î×¾²Àº¿ÀÌôÍý ; 17(2):165-174¡¤2014
  5. ÌÚ²¼Íøɧ ; Àº¿À¼À´µ¤ÎÎ×¾²¿À·ÐÀ¸Íý³Ø¤Ø¤Î±þÍÑ.ÆüËÜÀ¸Êª³ØŪÀº¿À°å³Ø²ñ»ï ; 25(2):113¡¤2014
  6. ÌÚ²¼Íøɧ ; Åý¹ç¼ºÄ´¾É¤ÎÀ¤³¦.ÆüËÜÉÂÀ׳زñ»¨»ï ; (87):4-9¡¤2014
  7. À¾ÅÄ·½°ìϺ, ÖÖË̲µ±, ²ÃÆ£Àµ¼ù ; ¿ç̲Ìô¤Î»È¤ï¤ìÊý¤ÈÃæÃÇÊýË¡ ¡½¹³¤¦¤ÄÌô(trazodone,mianserin,mirtazapine)¡½.Àº¿À²Ê¼£ÎÅ³Ø ; 29(11):1423-1425¡¤2014
  8. ²¬Â¼¹¨Èþ, µÈÌî¿¿µª, ÌÚ²¼Íøɧ ; ¹á·îÂÙÃˤΤ³¤³¤í¤Îµ°À×.ºÇ¿·Àº¿À°å³Ø ; 19(6)473-478¡¤2014
  9. µÈ¼¶©»Ë, ÖÖË̲µ±, ¿Ûˬ °´, À¾ÅÄ·½°ìϺ, ÌÚ²¼Íøɧ ; ·ì´ÉÀ­Ç§ÃÎ¾É ·ì´ÉÀ­Ç§Ãξɤμ£ÎŤÈͽ¸å.ÆüËÜÎ×¾² ; 72(Áý´©7 ºÇ¿·Î×¾²Ç¾Â´Ãæ³Ø -²¼-):610-613¡¤2014

¥Ú¡¼¥¸TOP¤ØÌá¤ë

Ãø½ñ

  1. ¥Ø¥¶¡¼Ž¥¥Ò¥ë(Ãø), »°ÂðâÃÍý, µÈ¼Àá»Ò(ÊÔ), »³¸ý¼ù»Ò(Ìõ), µÈ¼¶©»Ë¤Û¤« ; ǧÃξɤؤÎÈóÌôʪŪ´Ø¤ï¤ê.¥À¥ó¥¹¥³¥ß¥å¥Ë¥±¡¼¥·¥ç¥ó ǧÃξɤοͤȤĤʤ¬¤ëÎÏ ; 48 ¥¯¥ê¥¨¥¤¥Ä¤«¤â¤¬¤ï¡¤2014
  2. ²ÃÆ£Àµ¼ù ; ¹³¤¦¤ÄÌô¤ÎÉûºîÍÑ.º£Æü¤Î¼£ÎŻؿË2014ǯÈÇ »ä¤Ï¤³¤¦¼£ÎŤ·¤Æ¤¤¤ë 16Àº¿À¼À´µ ¹³¤¦¤ÄÌô¤ÎÉûºîÍÑ ; Vol.56:939-940 °å³Ø½ñ±¡¡¤2014
  3. ¶â ʸÈþ, ¶¶ËÜã»Ö, ¼¾åµ®±É ; »öÎã¤Ç¤ï¤«¤ë¥Ô¥¢¥µ¥Ý¡¼¥È¼ÂÁ© Àº¿À¾ã³²¼Ô¤ÎÃÏ°èÀ¸³è¤¬¤Ò¤í¤¬¤ë ; 1-244 Ãæ±ûË¡µ¬½ÐÈÇ¡¤2014
  4. ¿¥ÅÄ͵¹Ô, »³ÅÄÈÞº»»Ò, 𱩠ÆÆ, ÏÂÅľÈÊ¿ ; ÂçºåÉܼ«»¦Ì¤¿ë¼ÔÏ¢·È»Ù±ç»ö¶ÈÊó¹ð½ñ ; 1-57 ÂçºåÉÜ¡¦´ØÀ¾°å²ÊÂç³ØÁí¹ç°åÎÅ¥»¥ó¥¿¡¼¡¤2014
  5. ÖÖË̲µ± ; [¾ÉÎãÊÔ]­» ³Æ¹³Àº¿ÀÉÂÌô¤Î»È¤¤Êý¤Î¥³¥Ä¡½Í­¸ú¾ÉÎ㤫¤é¡½ 3.¥Ú¥í¥¹¥Ô¥í¥ó ¥Ú¥í¥¹¥Ô¥í¥óÅêÍ¿¤Ë¤è¤êÉ԰¾ɾõ¤ò´Þ¤á¤¿Àº¿À¾É¾õ¤Î²þÁ±¤¬ÆÀ¤é¤ì¤¿Åý¹ç¼ºÄ´¾É¤Î1Îã.Åý¹ç¼ºÄ´¾É¥±¡¼¥¹¥¹¥¿¥Ç¥£¡¼:¾ÉÎ㤬Ƴ¤¯¼Ò²ñÉüµ¢¡¦QOL¸þ¾å¤Ø¤ÎÆ» ; 110-112 ¥á¥Ç¥£¥«¥ë¥ì¥Ó¥å¡¼¼Ò¡¤2014
  6. ÅÏî´¹Õ°ìϺ, ¿Î²¦¿ÊÂÀϺ, ¿ù»³Äª¹¨, ÎëÌÚ±ÇÆó, µÆÃϽӶÇ, ²ÃÆ£Àµ¼ù ; ¹³¤¦¤ÄÌô¤Î¿ºÞÊ»ÍѤˤĤ¤¤Æ.Àº¿À¿À·Ð³Ø²ñ ; Àº¿À²ÊÌôʪÎÅË¡¸¦½¤²ñ e¥é¡¼¥Ë¥ó¥° ; Àº¿À¿À·Ð³Ø²ñ¥µ¥¤¥ÈÆâe¥é¡¼¥Ë¥ó¥° Àº¿À¿À·Ð³Ø²ñ¡¤2014

¥Ú¡¼¥¸TOP¤ØÌá¤ë